At a glance
- Originator MECT Corporation
- Developer MECT Corporation; Nonindustrial source
- Class Antineoplastics; Glycosides; Pyrimidine nucleosides
- Mechanism of Action CMP-sialic acid transport protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer metastases
Most Recent Events
- 26 May 2001 Profile reviewed but no significant changes made
- 14 Nov 1997 No-Development-Reported for Cancer metastases in Japan (Unknown route)
- 14 Nov 1997 No-Development-Reported for Cancer metastases in USA (Unknown route)